Targeting the Intracellular Environment in Cystic Fibrosis: Restoring Autophagy as a Novel Strategy to Circumvent the CFTR Defect
Valeria Rachela Villella, Speranza Esposito, Emanuela M. Bruscia, Maria Chiara Maiuri, Valeria Raia, Guido Kroemer, Luigi Maiuri

To cite this version:
Valeria Rachela Villella, Speranza Esposito, Emanuela M. Bruscia, Maria Chiara Maiuri, Valeria Raia, et al.. Targeting the Intracellular Environment in Cystic Fibrosis: Restoring Autophagy as a Novel Strategy to Circumvent the CFTR Defect. Frontiers in Pharmacology, Frontiers, 2013, 4, pp.1. <10.3389/fphar.2013.00001>. <hal-01578562>

HAL Id: hal-01578562
https://hal.sorbonne-universite.fr/hal-01578562
Submitted on 29 Aug 2017

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L’archive ouverte pluridisciplinaire HAL, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d’enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

Distributed under a Creative Commons Attribution 4.0 International License
Targeting the intracellular environment in cystic fibrosis: restoring autophagy as a novel strategy to circumvent the CFTR defect

Valeria Rachela Villella1, Speranza Esposito1, Emanuela M. Bruscia1,2, Maria Chiara Maiuri2,4, Valeria Raia5, Guido Kroemer6,7,8,9 * and Luigi Maiuri1,10 *

1 European Institute for Research in Cystic Fibrosis, San Raffaele Scientific Institute, Milan, Italy
2 Department of Pediatrics, Yale University School of Medicine, New Haven, CT USA
3 Department of Experimental Pharmacology, Federico II University, Naples, Italy
4 INSERM U848, Villejuif, France
5 Cystic Fibrosis Unit, Department of Pediatrics, Federico II University, Naples, Italy
6 Université Paris Descartes, Paris, France
7 Metabolomics Platform, Institut Gustave Roussy, Villejuif, France
8 Centre de Recherche des Cordeliers, Paris, France
9 Pôle de Biologie, Hôpital Européen Georges Pompidou, Assistance Publique – Hôpitaux de Paris, Paris, France
10 Institute of Pediatrics, University of Foggia, Foggia, Italy

Cystic fibrosis (CF) patients harboring the most common deletion mutation of the CF transmembrane conductance regulator (CFTR), F508del, are poor responders to potentiators of CFTR channel activity which can be used to treat a small subset of CF patients who genetically carry plasma membrane (PM)-resident CFTR mutants. The misfolded F508del-CFTR protein is unstable in the PM even if rescued by pharmacological agents that prevent its intracellular retention and degradation. CF is a conformational disease in which defective CFTR induces an impressive derangement of general proteostasis resulting from disabled autophagy. In this review, we discuss how rescuing Beclin 1 (BECN1), a major player of autophagosome formation, either by means of direct gene transfer or indirectly by administration of proteostasis regulators, could stabilize F508del-CFTR at the PM. We focus on the relationship between the improvement of peripheral proteostasis and CFTR PM stability in F508del-CFTR homozygous bronchial epithelia or mouse lungs. Moreover, this article reviews recent pre-clinical evidence indicating that targeting the intracellular environment surrounding the misfolded mutant CFTR instead of protein itself could constitute an attractive therapeutic option to sensitize patients carrying the F508del-CFTR mutation to the beneficial action of CFTR potentiators on lung inflammation.

Keywords: cystic fibrosis, CFTR, proteostasis regulators, autophagy, BECN1

INTRODUCTION

The proteostasis network ensures intracellular homeostasis in spite of genetic or epigenetic changes in protein conformation, extracellular stress, or aging-associated perturbations (Balch et al., 2008; Hutt et al., 2009; Powers et al., 2009; Gidalevitz et al., 2010; Hutt and Balch, 2010; Roth and Balch, 2011). The accumulation of misfolded/modified proteins due to mutations or due to the aging-related decline of proteostasis contributes to several human conformational diseases including neurodegenerative disorders and type II diabetes (Balch et al., 2008; Powers et al., 2009; Gidalevitz et al., 2010; Roth and Balch, 2011).

Cystic fibrosis (CF), the most common life-threatening genetic disease among Caucasians, constitutes the quintessential example of a “conformational disease” (Balch et al., 2011; Okiyoneda et al., 2011). CF is caused by mutations of the CF transmembrane conductance regulator (CFTR) gene that encodes a cAMP-regulated chloride channel primarily located at the apical membrane of epithelial cells (Quinton, 1999; Welsh et al., 2001; Park et al., 2010).

Although more than 1800 different mutations have been identified, one single deletion of phenylalanine at position 508 (F508del-CFTR), occurs in about 70–90% of CF patients in Northern Europe and North America (Bobadilla et al., 2002). F508del-CFTR protein can still retain a partial chloride channel activity if rescued at the epithelial surface. However, due to its misfold, F508del-CFTR does not reach the plasma membrane (PM) and is prematurely degraded, thus provoking local inflammation, increased susceptibility to respiratory bacterial infections, and progressive pulmonary and digestive insufficiency (O’Sullivan and Freedman, 2009; Ratjen, 2009).

The birth prevalence of CF is estimated to be one in 3500–4500, with 200–300 new cases each year in Europe. The typical form of CF is diagnosed during early childhood and is characterized by recurrent pulmonary infections, pancreatic insufficiency, and elevated chloride concentrations in sweat. Although CF is a systemic disease, the main cause of death is persistent and untreatable pulmonary Pseudomonas aeruginosa infection. Loss of functional
CFTR expression is thought to disturb the balance between fluid secretion and absorption into the epithelial layer, leading to net volume depletion of mucus, increased viscosity, and ineffective bacterial clearance. Bacterial infection in turn induces an increased inflammatory response and signaling, thus fueling a vicious cycle of mucus retention, infection, and inflammation.

Mounting evidences indicate that a constitutive inflammatory condition characterizes CF airways regardless of bacterial exposure. CFTR dysfunction results in constitutive, elevated NF-kB activation resulting in increased production of the pro-inflammatory chemokine, interleukin-8 (Vij et al., 2009; Belcher and Vij, 2010; Bodas and Vij, 2010; Hunter et al., 2010). Moreover, the lack of functional CFTR in macrophages has been reported to increase their responsiveness to inflammatory stimuli via uncontrolled TLR4 signaling (Bruscia et al., 2009, 2011) and to affect their capacity to kill *Pseudomonas aeruginosa* (Diet et al., 2006; Derij et al., 2009; Zhang et al., 2010; Del Porto et al., 2011). These findings support the role of CFTR dysfunction in favoring bronchopulmonary inflammation.

Advances in CF treatment have increased the median predicted survival age from less than 5 years in the 1940s to over 37 years presently (Davis, 2006). In addition to therapeutic approaches that target cellular events downstream of the CFTR defect (Mozzillo et al., 2009; Anderson, 2010; Belcher and Vij, 2010; Ratjen and Grasemann, 2012), other strategies focused on the basic CFTR defect have emerged (Riordan, 2008; Sloane and Rowe, 2010; Amaral, 2011; Lukacs and Verkman, 2012). To date, gene therapy has failed to demonstrate a clinical benefit for CF (Riordan, 2008; Amaral, 2011). Thus, pharmacological strategies aimed at correcting mutation-specific CFTR defects (CFTR-repairing therapies) have gained a prominent role in CF drug discovery.

The still partially functional F508del-CFTR protein can be rescued at the PM by means of experimental low thermal conditions (Denning et al., 1992), as well as by so-called correctors, which are molecules that avoid the intracellular retention and degradation of F508del-CFTR protein (Pedemonte et al., 2005; Verkman et al., 2006; Verkman and Galletta, 2009), as extensively reviewed by Molinski et al. and Pedemonte et al. in other chapters of this Special Topic. A number of CFTR corrector molecules have been identified by high-through put screening (Galletta et al., 2001; Pedemonte et al., 2005; Van Goor et al., 2006, 2011). Several CFTR correctors have proved their efficacy in rescuing F508del-CFTR in vitro. However, their efficacy in ameliorating the CF lung phenotype, either in pre-clinical models or in CF patients, has not yet established. A recent clinical trial with the most promising CFTR corrector, VX-809 (Van Goor et al., 2011), in F508del-CFTR homozygous patients demonstrated modest dose-dependent reductions in sweat chloride (Clancy et al., 2012). However, beyond this laboratory parameter, no improvement in lung function or CF-related airflow limitation was observed (Riordan et al., 2008; Okiyoneda et al., 2010). This seminal observation of Lukacs’ group can explain why CF patients carrying the misfolded F508del-CFTR respond poorly to molecules that increase the activity of CFTR channel (CFTR potentiator) (Davis, 2011; Ramsey et al., 2011). Indeed, the rescued F508del-CFTR is no longer available at the PM for the action of CFTR potentiators.

Therefore, combining CFTR correctors and potentiators may be a suitable approach for F508del-CFTR patients, provided that the corrector molecules are effective in increasing F508del-CFTR PM stability after rescue. Currently, phase II clinical studies evaluating the combination of VX-809 and the potentiator VX-770 in CF patients that express F508del-CFTR are underway (Elborn, 2012).

Restoration of a functional proteostasis network by the administration of proteostasis regulators (PRs) has emerged as a novel approach to correct protein misfolding in conformational diseases (Mu et al., 2008; Powers et al., 2009; Gidalievitz et al., 2010; Balch et al., 2011). Therefore, strategies aiming at manipulating peripheral proteostasis could represent a promising area of research in CF drug discovery. Understanding the mechanisms underlying the derangement of proteostasis consequent to defective CFTR function could help improving the search of new drug candidates for CF patients carrying F508del-CFTR mutants.

**THREE TO TANGO IN CYSTIC FIBROSIS: CFTR, TRANSGLUTAMINASE 2, AND AUTOPHagy**

**DEFECTIVE CFTR FUNCTION PERTURBS THE POST-TRANSLATIONAL NETWORK OF CF EPITHELIAL CELLS**

An impressive derangement of cellular homeostasis takes place in CF airways. Tissue transglutaminase (TG2) is upregulated in CF epithelial cells at the transcriptional and even more at the post-transcriptional levels (Mairi et al., 2008). TG2 is a versatile multifunctional protein that changes its function depending on external and internal signals (Nurminskaya and Belkin, 2012). In the presence of high Ca$^{2+}$ levels, TG2 works as a crosslinking enzyme, catalyzing several post-translational modifications of target proteins. At low Ca$^{2+}$ concentrations, TG2 may function as a G-protein or as a protein disulfide isomerase, thus contributing to the functionality of mitochondrial respiratory chain complexes (Nurminskaya and Belkin, 2012). Increased levels of TG2 are observed in several human pathologies including neurodegenerative diseases such as Alzheimer’s, Huntington’s, and Parkinson’s diseases, as well as in chronic inflammatory conditions (Taylor et al., 2003; Malorni et al., 2008; Iismaa et al., 2009; Mastrobernardino and Piacentini, 2010). Most proteins involved in the pathogenesis of neurodegenerative diseases, as huntingtin, ataxin1, tau, and alpha-synuclein, were reported to be TG2 substrates (Mastrobernardino and Piacentini, 2010). Increased TG2 expression has also been reported for glioblastomas, malignant melanomas, and pancreatic ductal adenocarcinomas. Moreover, TG2 expression is often associated with an increased metastatic activity or acquisition of drug-resistance (Antonyak et al., 2004; Karin and Greten, 2005; Kim et al., 2006; Satpathy et al., 2007).

In CF airway epithelial cells, TG2 undergoes small ubiquitin-like-modifier (SUMO)ylation (Luciani et al., 2009), a post-translational modification that affects the stability and functions of proteins. SUMOylation is a key player of the post-translational network as it regulates transcription, nuclear translocation, stress
responses, and chromatin structure. Moreover, it influences intracellular localization and stability of modified proteins (Geiss-Friedlander and Melchior, 2007; Meulmeester and Melchior, 2008; Tempe et al., 2008). SUMOylation is accomplished by an enzymatic cascade that involves E3 ligases which orchestrate SUMO modifications in response to stress. We discovered that the protein inhibitor of activated STAT (PIAS)y, which is induced by reactive oxygen species (ROS) and participates in the SUMOylation of NF-κB essential modulator (NEMO) upon genotoxic stress (Mabb and Wuerzberger-Davis, 2006), is upregulated in CF epithelia in response to oxidative stress and then mediates SUMOylation of TG2 (Luciani et al., 2009). Indeed, TG2 contains three SUMO acceptor sites (consensus sequence: ψψ_kxE) in its sequence. SUMOylation of lysines is incompatible with the Ubiquitination of these residues (Muller and Hoege, 2001). Thus, TG2 SUMOylation ultimately results in the inhibition of TG2 ubiquitination, thereby preventing its proteasomal degradation. This sustains high intracellular TG2 protein levels, coupled to prolonged TG2 enzyme activation as the result of the elevated Ca^{2+} content. Indeed, emerging evidence support the role of elevated intracellular calcium concentration in mediating the signaling events that impair homeostasis in CF epithelia, as reviewed by Antigny et al. (2011a) in another chapter of this Special Topic. Although the mechanisms underlying the disturbed calcium homeostasis observed in CF remain incompletely understood, recent studies suggest that impaired calcium signaling may be the result of either increased agonist-mediated activation of G-protein-coupled receptors or abnormal regulation of calcium storage compartments (Egan et al., 2002, 2004; Ribeiro et al., 2005a,b; Norez et al., 2006a,b; Martino et al., 2009). Moreover, the abnormal Ca^{2+} response observed in CF cells depends on the presence of CFTR at the cell surface and this reciprocal regulation of CFTR and Ca^{2+} channels has been described in the literature (Antigny et al., 2011b).

Therefore, in CF, increased intracellular levels of ROS, induced by defective CFTR function, lead to the upregulation of the SUMO E3-ligase PIASy, which facilitates TG2 SUMOylation, persistent high TG2 protein levels, and sustained TG2 activation as the result of “permissive” elevated Ca^{2+} levels. The presence of high TG2 levels might in turn sustain ROS, as it is known that TG2 may stimulate the activity of the mitochondrial respiratory chains (Malorni et al., 2008). Remarkably, inhibiting CFTR, either by gene silencing or by means of pharmacological inhibitors, recapitulates these post-translational modifications of TG2 through upregulating ROS levels in cell lines expressing wild-type (wt)-CFTR (Luciani et al., 2009).

These post-translational changes of TG2 protein, induced by defective CFTR, may have functional implications in epithelial homeostasis. Sustained TG2 activation leads to crosslinking, increased ubiquitination, and functional sequestration of the TG2 substrates peroxisome proliferator-activated receptor (PPAR)y and IκBα (Daynes and Jones, 2002; Kim et al., 2006; Mauri et al., 2008). Indeed, the anti-inflammatory molecule PPARy undergoes SUMOylation in response to its agonists, thus interacting with the N-CoR-histone deacetylase (HDAC) 3 co-repressor complex to maintain a repressor condition (Pascual et al., 2005). TG2-mediated ubiquitination of PPARy inhibits its SUMOylation and interaction with N-CoR. Similarly, crosslinking and ubiquitination of IκBα inhibits IκBα SUMOylation and favors NF-κB activation and nuclear translocation (Luciani et al., 2009). Both events were reported to favor inflammation in CF airways. Therefore, TG2 can function as a rheostat of the post-translational network in response to CF-associated oxidative stress. TG2 SUMOylation with sustained TG2 activation switches off the post-translational regulatory mechanisms and perturbs the intracellular environment (Figure 1).

TG2-mediated protein ubiquitination and crosslinking may lead to protein aggregation and proteasome overload, thus favoring aggresome formation (Muma, 2007; Dohm et al., 2008). Misfolded or post-translationally modified proteins that cannot be degraded by the proteasome machinery can be stocked in the cytoplasm in the form of aggresomes (Kawaguchi et al., 2003; Kirkin et al., 2009). Accordingly, ubiquitylated PPARy and IκBα aggregates are sequestered within histone-deacetylase (HDAC)6^{+}/vimentin^{+} intracellular aggresomes in CF epithelial cells (Figure 2).

Therefore, proteostasis of F508del-CFTR epithelia is affected by a combination of genetic defect (resulting from the misfolded CFTR protein) and post-translational alterations (through the ROS/TG2 axis).

TG2 is localized in multiple cellular compartments including cell surface and extracellular matrix. Besides its crosslinking activity on ECM substrates, extracellular TG2 is also endowed with PDI, or GTPase functions (Nurminskaya and Belkin, 2012). However, the potential relevance of the extracellular TG2 in CF is still unknown.

**DEFECTIVE CFTR DISABILITIES AUTOPHAGY**

Given the overproduction of ROS together with the endoplasmic reticulum (ER) stress induced by the mutant CFTR, one would expect an activation of autophagy in F508del-CFTR homoygous epithelial cells. Autophagy is pivotal in promoting cellular clearance of protein aggregates and removal of ROS sources, such as damaged mitochondria (Mizushima et al., 2008; Kirkin et al., 2009; Korolchuk et al., 2009; Kroemer et al., 2010; Moreau et al., 2010). Surprisingly, however, human and mouse CF airways exhibit a pronounced defect in autophagy, as indicated by reduced autophagosome formation, and the accumulation of sequestosome 1 (SQSTM1), a major autophagic substrate also known as p62. This occurs in spite of the normal expression of major autophagy genes (Luciani et al., 2010, 2011). A defective autophagic response to bacterial infection has also been reported in murine CF macrophages. Reduced autophagosome formation in CF macrophages promotes *Burkholderia cenocepacia* survival and hypersecretion of IL-1β (Abdulrahman et al., 2011).

Autophagy results in the lysosomal degradation of cytoplasmic organelles or cytosolic components after their sequestration in two-membraned vesicles (Kroemer et al., 2010; Yang and Klionsky, 2010; Codogno et al., 2011; Mizushima et al., 2011). In the last few years, autophagy has emerged not just as a simply degradative process, but also as a cellular mechanism essential for the maintenance of cellular homeostasis and of the energetic balance (Kroemer et al., 2010). Thus, disabled autophagy is associated with and is relevant to several human diseases including cancer, viral infection, neurodegenerative diseases, respiratory pathologies, and
FIGURE 1 | Defective CFTR-induced perturbation of the post-translational network in CF epithelial cells. Defective CFTR leads to increased levels of reactive oxygen species (ROS) that increase the levels of the SUMO E3-ligase PIASy, causing TG2 SUMOylation, that, in turn, inhibits TG2 ubiquitination, and avoids its proteosomal degradation, thus sustaining increased TG2 protein levels. Sustained TG2 activation mediates crosslinking of PPARγ and IκB, which undergo ubiquitination and proteasome degradation. This inhibits nuclear translocation of PPARγ and favors nuclear translocation of NF-κB, stimulating inflammation.

Chronic inflammatory disease (Levine et al., 2011; Rubinsztein et al., 2011; Sridhar et al., 2012; Patel et al., 2013).

Through which mechanisms is autophagy inhibited in CF? We have demonstrated that the inhibition of autophagy in CF epithelial cells is part of the complex perturbation of the post-translational network consequent to defective CFTR function. Disabled autophagy in CF epithelial cells is a consequence of TG2-mediated crosslinking and functional sequestration of BECN1, a major player of autophagosome formation, which exhibits target sites (QP, QxxP) for crosslinking by TG2 (Luciani et al., 2010).

BECN1 is a haploinsufficient tumor suppressor protein that is essential for autophagy (Sinha and Levine, 2008; He and Levine, 2010; Maiuri et al., 2010). Accumulating evidence indicate that BECN1 dissociates from Bcl-2 during stress conditions, such as starvation, thus promoting autophagy (Pattingre et al., 2005; Maiuri et al., 2007, 2010; Axe et al., 2008; Hayashi-Nishino et al., 2009). Subsequently, BECN1 interacts with the class III phosphatidylinositol-3 kinase (PI3K), human vacuolar protein sorting (hVps)34 (Matsunaga et al., 2009; Zhong et al., 2009), facilitating its activation. The ER-associated class III PI3K activity is crucial for the initiation of autophagosome formation (Axe et al., 2008; Hayashi-Nishino et al., 2009).

Reduced BECN1/Bcl-2 interaction upon starvation is observed in CF cells, suggesting an intracellular environment favorable to autophagy induction. Moreover, BECN1 interacts with the essential components of the PI3K complex IIIhVps34, hVps15, Ambra1, as well as with Atg14L, a BECN1 interactor that diverts hVps/Class III PI3K into an autophagic role (Li et al., 2008; Matsunaga et al., 2009). However, in CF epithelial cells, the BECN1 interac-tome is dislodged away from the ER as a consequence of BECN1 crosslinking and is sequestered within HDAC6+ aggresomes. This impairs autophagosome formation in CF cells (Luciani et al., 2010).

Autophagy deficient CF cells accumulate SQSTM1 (p62), an ubiquitin-binding (and LC3-binding) protein (Bjørkøy et al., 2005; Kirkin et al., 2009; Mathew et al., 2009; Duran et al., 2011) that is selectively degraded by autophagy. Autophagy upregulation has been reported as a compensatory response to proteasome inhibition, thus revealing a crosstalk between the proteasome-based and the autophagy-based degradation pathways (Komatsu et al., 2007; Kirkin et al., 2009; Korolchuk et al., 2009; Lamark and Johansen, 2010). SQSTM1 accumulation resulting from autophagy inhibition contributes to proteasome overload and favors aggresome formation, while disabled autophagy inhibits the clearance of such protein aggregates. Altogether, the combined inhibition of protein and aggresome turnover may also influence the fate of misfolded CFTR. Indeed, the enforced expression of F508del-CFTR in CF epithelial cell...
Defective CFTR-mediated inhibition of autophagy in CF epithelial cells. Defective CFTR-mediated TG2 activation leads to BECN1 crosslinking and displaces BECN1 interactome away from the endoplasmic reticulum (ER). This mislocalization inhibits autophagosome formation, disables autophagy, and induces accumulation of SQSTM1 (p62). SQSTM1 accumulation leads to proteasome overload and favors sequestration of cross-linked TG2 substrates (PPARγ, IκBα, BECN1) within HDAC6+ aggresomes. The combined inhibition of protein and aggresome turnover may also favor the accumulation of F508del-CFTR (together with SQSTM1) within HDAC6+ ubiquitin+ intracellular aggregates. Defective autophagy inhibits the clearance of damaged mitochondria that contribute to the generation of pro-inflammatory ROS.

Lines favors the accumulation of misfolded CFTR (together with SQSTM1) within HDAC6+/ubiquitin+ intracellular aggregates (Luciani et al., 2010).

We suggest that this cascade of events can generate a vicious feed-forward loop, as it impairs the clearance of damaged mitochondria, thus increasing ROS generation that in turn enhances TG2 activation and BECN1 sequestration, further sustaining airway inflammation (Figure 2).

RESTORING PROTEOSTASIS AMELIORATES LUNG INFLAMMATION THROUGH RESCUING AUTOPHAGY IN CF

Inhibiting TG2 activity by cystamine (and its reduced form cysteamine) or targeting ROS can reduce inflammation in F508del-CFTR airways, both in vivo in F508del-CFTR homozygous mice (Cftr<sup>F508del</sup> mice) and in ex vivo using explanted human polyp biopsies from CF patients (Raia et al., 2005; Luciani et al., 2010). The effects of cystamine on airway inflammation are mediated by its ability to rescue BECN1 and autophagy, as either BECN1 depletion used in vitro or administration of the PI3K complex III inhibitor 3-methyl-adenine (3-MA) used in vivo in Cftr<sup>F508del</sup> mice, abrogated these beneficial effects of cystamine. Either enforced BECN1 overexpression or SQSTM1 depletion in vivo recapitulated the effects of cystamine in ameliorating lung inflammation in Cftr<sup>F508del</sup> mice (Luciani et al., 2010, 2012). Similarly, cystamine has already been successfully used in mouse models of Huntington’s disease to improve disease-related phenotype (Karpuj et al., 2002).

Importantly, we demonstrated that amelioration of lung inflammation in Cftr<sup>F508del</sup> mice secondary to cystamine treatment persists up to 10 days beyond cystamine withdrawal, unless the rescue of BECN1 and autophagy are inhibited by the administration of 3-MA during washout (Luciani et al., 2012). These data suggest the provocative hypothesis that, once the cellular environment has been re-directed toward a physiological status, a driving force is re-established within the cell, so as to prolong these beneficial effects. Could this “newly re-established” player be the functional CFTR itself at the epithelial surface? Indeed, manipulating proteostasis might actually improve the function of misfolded proteins (Balch et al., 2008; Roth and Balch, 2011).

TARGETING AUTOPHAGY AS A NEW STRATEGY TO ENABLE THE ACTION OF CFTR POTENTIATORS ON F508del-CFTR

F508del-CFTR rescued at the PM by means of corrector strategies is rapidly dismissed and re-directed to lysosomes for degradation (Sharma et al., 2004; Okiyoneda et al., 2010, 2011; Lukacs
and Verkman, 2012). Accordingly, the biochemical half-life of PM F508del-CFTR is lower than 4 h (Lukaes et al., 1993; Hedj et al., 2001). Therefore, F508del-CFTR is no longer present at the PM and cannot interact with CFTR potentiators after rescue.

Recently, we have reported that overexpression of BECN1, administration of cystamine, or depletion of SQSTM1 by RNA interference, can favor the trafficking of F508del-CFTR protein to the epithelial cell surface in vitro in CF epithelial cell lines (CFBE41o- or IB3-1, carrying F508del/F508del or F508del/W1282X CFTR, respectively), ex vivo in nasal polyp biopsies from CF patients, and in vivo in CftrF508del mice. Interestingly, these treatments can restore a functional CFTR in CF cell lines and in primary brushed nasal epithelial cells from F508del-CFTR homozygous patients (Luciani et al., 2012).

Therefore, PR-based strategies in CF (as administration of cystamine or genetic restoration of BECN1) may have a dual effect, as they reduce lung inflammation while rescuing a functional mutant CFTR to the epithelial surface.

TARGETING AUTOPHAGY IMPROVES F508del-CFTR PM STABILITY IN AIRWAY CF EPITHELIA WELL BEYOND DRUG WASHOUT

In addition to its ability to rescue F508del-CFTR, cystamine is effective in delaying the disposal of PM resident F508del-CFTR protein and generates permissive conditions to prolong F508del-CFTR PM residence well beyond cystamine washout. These effects are mediated by the ability to restore BECN1 and autophagy, as both BECN1 depletion and 3-MA abrogate the beneficial effects of cystamine. PM resident mutant F508del-CFTR is still functional after cystamine withdrawal, as it retains the ability to respond to forskolin added together with CFTR potentiators (as genistein or VX-532 or VX-770) well beyond the washout period. This prolonged function of F508del-CFTR was observed in CF cell lines, as well as in primary brushed nasal epithelial cells from F508del-CFTR homozygous patients. Moreover, cystamine sustains F508del-CFTR re-location at the lung epithelial surface after 10 days following washout in vivo in CftrF508del mice, unless that cystamine was combined with 3-MA (Luciani et al., 2012).

These effects of cystamine can explain how the anti-inflammatory effects as a result of the restoration of autophagy (either via pharmacological intervention, as cystamine, or by the enforced expression of BECN1) persist well beyond its withdrawal in CftrF508del mice. They probably rely on CFTR itself. Indeed, the pro-autophagic effects of cystamine persist after 10 days following cystamine withdrawal unless CFTR was depleted during washout, suggesting that these anti-inflammatory effects are mediated by the ability to sustain a functional CFTR at the cell surface (Luciani et al., 2012). Therefore, sustained CFTR function at the PM can interrupt the cascade of ROS generation, TG2 activation, BECN1 sequestration, and autophagy inhibition, and ultimately reduce lung inflammation.

These findings could also explain how cystamine, which is not an autophagy inducer, is highly effective in restoring autophagy within a "CF environment." The fact that cystamine can regulate peripheral protoxosis is also supported by the observation that cystamine (but not CFTR correctors as VX-325 or Corr-4a) is effective in sustaining PM stability of F508del-CFTR even if it has previously been rescued at the PM by low temperature.

TARGETING AUTOPHAGY ENABLES THE BENEFICIAL ACTION OF POTENTIATORS ON F508del-CFTR

These findings indicate that PRs may be used to rescue and stabilize F508del-CFTR at the PM of CF epithelial cells. In principle, this strategy could lower the ER quality control (QC) threshold of all misfolded proteins, thus interfering with the QC fidelity. However, besides its effects on F508del-CFTR rescue at the PM, cystamine can also delay the disposal of PM resident F508del-CFTR protein. The evidence discussed in this review supports that defective CFTR suppresses autophagy within the CF epithelial environment (though the ROS/TG2 pathway), and, conversely, that rescuing autophagy can restore a functional CFTR at the PM. Altogether, these insights suggest the existence of a vicious cycle in which defective CFTR functions destabilizes the CFTR protein and that can be interrupted by cystamine.

Considering these factors, one would expect that sustaining PM residence of F508del-CFTR by PRs, could allow potentiators to improve Cl− transport through PM resident CFTR molecules. Indeed, our recent data indicate that, if proteostasis has been previously restored by cystamine, potentiators can become effective in sustaining the anti-inflammatory effects of cystamine in vivo in CftrF508del mice. Importantly, genistein, which has no effects on its own in CftrF508del mice, synergistically interacts with cystamine to reduce lung inflammation triggered by the challenge with lipopolysaccharide (LPS) from Pseudomonas aeruginosa. The same effects are observed if proteostasis has been previously re-established in CftrF508del mice by means of genetic manipulations, such as lentiviral expression of BECN1 or shRNA-mediated depletion of SQSTM1 (Luciani et al., 2012).

These observations indicate that pharmacological measures that ameliorate the cellular environment in which mutant CFTR traffics, instead of specifically targeting the misfolded protein itself, can result in improved disease outcome.

PERSPECTIVES

CFTR-REPAIRING STRATEGIES AND ANTI-INFLAMMATORY THERAPIES: TWO SIDES OF THE SAME COIN?

The data discussed in this review suggest that different approaches could be envisaged to control CF lung inflammation. Some therapies focus on conventional or emerging anti-inflammatory molecules, downstream of CFTR. Others, as cystamine and other yet-to-be-developed PRs, rely on the rescue and stabilization of functional CFTR at the PM. Apparently, cystamine can interrupt the dangerous cycle leading to lung inflammation, thus opening a new scenario in the search of the most appropriate CFTR-repairing strategy.

Searching the appropriate CFTR corrector is a challenging issue in drug development. An ideal drug candidate for the treatment of F508del-CFTR patients should not only aim at rescuing trafficking of mutant CFTR, be it through the conventional Golgi-mediated exocytic pathway (Ward et al., 1995; Quinlton, 1999; Amalar, 2004, 2011) or the unconventional GRASP-dependent secretory pathway (Gee et al., 2011), but also at sustaining the rescued mutant CFTR at the PM, to allow the combined action of potentiators on PM resident F508del-CFTR. Ideally, one single molecule should be endowed with all these properties to minimize undesirable effects. Our recent observations suggest that F508del-CFTR patients could
be sequentially treated with two single pharmacological agents, first with cystamine and then with CFTR potentiators.

The findings discussed in this review also highlight the importance of testing F508del-CFTR correctors for their capacity to exert a prolonged control of lung inflammation in pre-clinical models, before initiating clinical trials. So far, our strategy has been successfully tested in nasal polybiopsy samples from F508del-CFTR homozygous patients as well as in vivo in F508del-CFTR homozygous mice (Luciani et al., 2012). At this stage, clinical trials on CF patients are justified.

ACKNOWLEDGMENTS

This was supported by the European Institute for Research in Cystic Fibrosis and Italian Cystic Fibrosis Association (Luigi Maiuri), the Programma di Ricerca Scientifica di Rilevante Interesse Nazionale (2008RMJ3B3A_004, 2008) of the Ministero dell’Istruzione, dell’Università e della Ricerca (Luigi Maiuri, Valeria Raia), R10 HL093004 (Emanuela M. Bruscia), Telethon Grant # GGP12128 (Luigi Maiuri, Emanuela M. Bruscia, Valeria Raia, Maria Chiara Maiuri), Ligue Nationale contre le Cancer (Equipe labellisée; Guido Kroemer), AXA Chair for Longevity Research, Agence Nationale pour la Recherche (ANR; Guido Kroemer), European Commission (Active p35, Apo-Sys, ChemoRes, ApoTrain; Guido Kroemer), Foundation pour la Recherche Médicale (FRM), Institute National du Cancer (INCa), Cancéropôle Ile-de-France (Guido Kroemer), Fondation Bettencourt-Schueller, and the LabEx Onco-Immunology (Guido Kroemer).

REFERENCES

Abdulrahman, B. A., Khweek, A. A., Akhter, A., Caution, K., Kotrange, S., Abdelaziz, D. H., et al. (2011). Autophagy stimulation by rapamycin suppresses lung inflammation and infection by Burkholderia cenocepacia in a model of cystic fibrosis. Autophagy 7, 1359–1370.

Amaral, M. D. (2004). CFTR and cystic fibrosis. J. Mol. Neurosci. 23, 41–48.

Amaral, M. D. (2011). Targeting CFTR: how to treat cystic fibrosis by CFTR-repairing therapies. Curr. Drug Targets 12, 683–693.

Anderson, P. (2010). Emerging therapies in cystic fibrosis. Thor. Adv. Respir. Dis. 4, 177–185.

Antigny, F., Norez, C., Becq, F., and Vandenbrouck, C. (2011a). CFTR and Ca2+ signaling in cystic fibrosis. Front. Pharmacol. 2:67. doi:10.3389/fphar.2011.00067

Antigny, F., Norez, C., Dannhofer, L., Bertrand, J., Raveau, D., Corbi, P., et al. (2011b). Transient receptor potential canonical channel 6 links Ca2+ mishandling to cystic fibrosis transmembrane conductance regulator channel dysfunction in cystic fibrosis. Am. J. Respir. Cell Mol. Biol. 44, 83–90.

Antonyak, M. A., Miller, A. M., Jensen, J. M., Boehm, J. E., Balkman, C. E., Wakslag, J. J., et al. (2004). Augmentation of tissue transglutaminase expression and activation by epidermal growth factor inhibitor dominbucin-induced apoptosis in human breast cancer cells. J. Biol. Chem. 279, 41461–41467.

Axe, E. L., Walker, S. A., Manilava, M., Chandra, P., Roderick, H. L., Habermann, A., et al. (2008). Autophagosome formation from membrane compartments enriches phosphatidylinositol 3-phosphate and dynamically connected to the endosomal reticulum. J. Cell Biol. 182, 685–701.

Balch, W. E., Morimoto, R. I., Dillin, A., and Kelly, J. W. (2008). Adapting proteostasis for disease intervention. Science 319, 916–919.

Balch, W. E., Roth, D. M., and Hutt, D. M. (2011). Emergent properties of proteostasis managing cystic fibrosis. Cold Spring Harb. Perspect. Biol. 3, pii:a004499.

Belcher, C. N., and Vij, N. (2010). Protein processing and inflammation signaling in cystic fibrosis: challenges and therapeutic strategies. Curr. Mol. Med. 10, 82–94.

Björkøy, G., Lamark, T., Brech, A., Utzun, H., Perander, M., Overvatn, A., et al. (2005). p27SQSTM1 forms protein aggregates degraded by autophagy and has a protective effect on huntingtin-induced cell death. J. Cell Biol. 171, 683–614.

Bodalla, J. L., MacElk, M. Jr., Fine, J. P., and Farrell, P. M. (2002). Cystic fibrosis: a world wide analysis of CFTR mutations–correlation with incidence data and application to screening. Hum. Mutat. 19, 575–606.

Bodas, M., and Vij, N. (2010). The NFR2-kappal signaling in cystic fibrosis lung disease: pathophysiology and therapeutic potential. Discov. Med. 9, 346–356.

Bruscia, E. M., Zhang, P. X., Ferreira, E., Caputo, C., Emerson, I. W., Tuck, D., et al. (2009). Macrophages directly contribute to the exacerbated inflammatory response in cystic fibrosis transmembrane conductance regulator−/− mice. Am. J. Respir. Cell Mol. Biol. 40, 289–304.

Bruscia, E. M., Zhang, P. X., Satoth, A., Caputo, C., Medzhitov, R., Shenoy, A., et al. (2011). Abnormal trafficking and degradation of TLR4 underlie the elevated inflammatory response in cystic fibrosis. J. Immunol. 186, 6990–6998.

Clancy, J. P., Rowe, S. M., Accurso, F. J., Aitken, M. L., Amin, R. S., Ashlock, M. A., et al. (2012). Results of a phase II study of VX-809, an investigational CFTR corrector compound, in subjects with cystic fibrosis homozygous for the F508del-CFTR mutation. Thorax 67, 12–18.

Cedogno, P., Mehrpour, M., and Pirokas-Cezanne, T. (2011). Canonical and non-canonical autophagy: variations on a common theme of self-eating? Nat. Rev. Mol. Cell Biol. 13, 7–12.

Davis, P. B. (2006). Cystic fibrosis since 1938. Am. J. Respir. Crit. Care Med. 173, 475–482.

Davis, P. B. (2011). Therapy for cystic fibrosis – the end of the beginning? N. Engl. J. Med. 365, 1734–1735.

Daynes, R. A., and Jones, D. C. (2002). Emerging roles of PPARs in inflammation and immunity. Nat. Rev. Immunol. 2, 748–759.

Del Porto, P., Cifani, N., Guarnieri, S., Di Domenico, E. G., Marigó, M. A., Spadaro, F., et al. (2011). Dysfunctional CFTR alters the bacterial activator of human macrophages against Pseudomonas aeruginosa. PLoS ONE 6:e194970. doi:10.1371/journal.pone.0019970

Denning, G. M., Anderson, M. P., Amara, J. E., Marshall, J., Smith, A. E., and Welsh, M. J. (1992). Processing of mutant cystic fibrosis transmembrane conductance regulator is temperature-sensitive. Nature 358, 761–764.

Dery, L. V., Gomez, E. A., Zhang, G., Beacham, D. W., Hopson, J. A., Gallan, A. J., et al. (2009). Disease-causing mutations in the cystic fibrosis transmembrane conductance regulator determine the functional responses of alveolar macrophages. J. Biol. Chem. 284, 35926–35938.

Díaz, A., Brown, M. E., Derity, L. V., Li, C., Sneto, F. L., Chen, Y., et al. (2006). CFTR regulates phagosome acidification in macrophages and alters bactericidal activity. Nat. Cell Biol. 8, 933–944.

Dohm, C. P., Kerner, P., and Bahr, M. (2008). Aggregopathy in neurodegenerative diseases: mechanisms and therapeutic implication. Neurodegener. Dis. 5, 321–338.

Durán, A., Amanchy, R., Linares, J. F., Joshi, J., Abu-Baker, S., Porollo, A., et al. (2011). p62 is a key regulator of nutrient sensing in the mTORC1 pathway. Mol. Cell 44, 134–146.

Egan, M. E., Glassker-Pagel, J., Ambrose, C., Cahill, P. A., Pappoe, L., Balamuth, N., et al. (2002). Calcium-pump inhibitors induce functional surface expression of Delta F508-CFTR protein in cystic fibrosis epithelial cells. Nat. Med. 8, 485–492.

Egan, M. E., Pearson, M., Weiner, S. A., Rajendran, V., Rubin, D., Glassker-Pagel, J., et al. (2004). Curcumin, a major constituent of turmeric, corrects cystic fibrosis defects. Science 304, 600–602.

Elborn, J. S. (2012). Fixing cystic fibrosis CFTR with correctors and potentiators. Off to a good start. Thorax 67, 4–5.

Galletta, L. J., Springstel, M. F., Eda, M., Niedeniski, E. J., By, K., Haddadin, M. J., et al. (2001). Novel CFTR chloride channel activators identified by screening of combinatorial libraries based on flavone and benzoquinolinizinium lead compounds. J. Biol. Chem. 276, 19723–19728.

Gee, H. Y., Noh, S. H., Tang, B. L., Kim, K. H., and Lee, M. G. (2011). Rescue of DF508-CFTR. Trafficking via a GRASP-dependent unconventional secretion pathway. Cell 146, 746–760.

Geiss-Friedlander, R., and Melchior, F. (2007). Concepts in sumoylation: a decade on. Nat. Rev. Mol. Cell Biol. 8, 947–956.
Autophagy fights disease through cellular self-digestion. Nature 28, 1069–1075.

Mizushima, N., Yoshimori, T., and Ohsumi, Y. (2011). The role of Atg proteins in autophagosome formation. Annu. Rev. Cell Dev. Biol. 27, 107–132.

Moreau, K., Luo, S., and Rubinsztein, D. C. (2010). Cytoprotective roles for autophagy. Curr. Opin. Cell Biol. 22, 206–211.

Mozzillo, E., Franzen, A., Valerio, G., Sepe, A., De Simone, I., Mazzarella, G., et al. (2009). One-year glargine treatment can improve the course of lung disease in children and adolescents with cystic fibrosis and early glucose derangements. Pediatr. Diabetes 10, 162–167.

Mu, T. W., Ong, D. S., Wang, Y. J., Balch, W. E., Yates, J. R. III, Segatori, L., et al. (2008). Chemical and biological approaches synergize to ameliorate protein-folding diseases. Cell 134, 769–781.

Munoz, N. A. (2007). Transglutaminase is linked to neurodegenerative disease. J. Neurotraf. Exp. Neurol. 66, 258–263.

Muller, S., and Hoegen, C. (2001). SUMO-I, ubiquitin’s mysterious cousin. Nat. Rev. Mol. Cell Biol. 2, 202–210.

Norez, C., Antigny, F., Becq, F., and Vandebrouck, C. (2006a). Maintaining low Ca2+ level in the endoplasmic reticulum restores abnormal endogenous F508del-CFTR trafficking in airway epithelial cells. Traffic 7, 562–573.

Norez, C., Noel, S., Wilke, M., Bijeveld, M., Jorna, H., Melin, P., et al. (2006b). Rescue of functional deltaF508-CFTR channels in cystic fibrosis epithelial cells by the alpha-glucosidase inhibitor miglustat. FERS Lett. 580, 2081–2086.

Nurminksiaya, M. V., and Belkin, A. M. (2012). Cellular functions of tissue transglutaminase. Int. Rev. Cell. Mol. Biol. 294, 1–97.

Okiyoneda, T., Apajä, P. M., and Lukacs, G. L. (2011). Protein quality control at the plasma membrane. Curr. Opin. Cell Biol. 23, 483–491.

Okiyoneda, T., Barriere, H., Bagdany, M., Rabeh, W. M., Du, K., Hohfeld, J., et al. (2010). Peripheral protein quality control removes unfolded CFTR from the plasma membrane. Science 329, 805–810.

O’Sullivan, B. P., and Freedman, S. D. (2009). Cystic fibrosis. Lancet 373, 1891–1904.

Park, H. W., Nam, J. H., Kim, J. Y., Namkung, W., Yoon, J. S., Lee, J. S., et al. (2010). Dynamic regulation of
CFTR bicarbonate permeability by [Cl–]i and its role in pancreatic bicarbonate secretion. *Gastroenterology* 139, 620–631.

Pascual, G., Fong, A. L., Ogawa, S., Gamiel, A., Li, A. C., Perissi, V., et al. (2005). A SUMOylation-dependent pathway mediates transrepression of inflammatory response genes by PPAR-y. *Nature* 437, 759–763.

Patel, A. S., Morse, D., and Choi, A. M. (2013). Regulation and functional significance of autophagy in respiratory cell biology and disease. *Am. J. Respir. Cell Mol. Biol.* 48, 1–9.

Pattingre, S., Tassa, Q., Xu, Q., Garutti, R., Liang, X. H., Mizushima, N., et al. (2005). Bcl-2 antiproteasomal proteins inhibit Beclin 1-dependent autophagy. *Cell* 123, 927–939.

Pedemonte, N., Lukacs, G. L., Du, K., Caci, E., Zegarra-Moran, O., Gaillet, L. J., et al. (2005). Small-molecule correctors of defective [Delta]F508-CFTR cellular processing identified by high-throughput screening. *J. Clin. Invest.* 115, 2564–2571.

Powers, E. T., Morimoto, R. I., Dillin, A., Kelly, J. W., and Balch, W. E. (2009). Biological and chemical approaches to diseases of proteostasis deficiency. *Annu. Rev. Biochem.* 78, 959–991.

Quinton, P. M. (1999). Physiological basis of cystic fibrosis: a historical perspective. *Physiol. Rev.* 79(Suppl. 1), S3–S22.

Raia, V., Masiur, L., Ciacci, C., Ricciardelli, I., Vaccar, L., Auricchio, S., et al. (2005). Inhibition of p38mitogen activated protein kinase controls airway inflammation in cystic fibrosis. *Thorax* 60, 773–780.

Ramsey, B. W., Davies, J., McElvaney, N. G., Tollis, U., Bell, S. C., Drevinek, P., et al. (2011). A CFTR potentiator in patients with cystic fibrosis and the G551D mutation. *N. Engl. J. Med.* 365, 1663–1672.

Ratjen, F., and Grasemann, H. (2012). New therapies in cystic fibrosis. *Front. Pharmacol.* 3, 108, 18843–18848.

Ratjen, F., A. (2009). Cystic fibrosis: pathogenesis and future treatment strategies. *Respir. Care* 54, 595–605.

Ribeiro, C. M., Paradiso, A. M., Carew, M. A., Shears, S. B., and Boucher, R. C. (2005a). Cystic fibrosis airway epithelial Ca2+ i-signaling: the mechanism for the larger agonist-mediated Ca2+ i signals in human cystic fibrosis airway epithelia. *J. Biol. Chem.* 280, 10202–10209.

Ribeiro, C. M., Paradiso, A. M., Schwab, U., Perez-Vilar, J., Jones, L., O’Neal, W., et al. (2005b). Chronic airway inflammation/infection induces a Ca2+ i-dependent hyperinflammatory response in human cystic fibrosis airway epithelia. *J. Biol. Chem.* 280, 17798–17806.

Riordan, J. R. (2008). CFTR function and prospects for therapy. *Annu. Rev. Biochem.* 77, 701–726.

Roth, D. M., and Balch, W. E. (2011). Modeling general proteostasis: protein balance in health and disease. *Curr. Opin. Cell Biol.* 23, 126–134.

Rubinstein, D. C., Marínó, G., and Kroemer, G. (2011). Autophagy and aging. *Cell* 146, 682–695.

Saltatory, M., Cao, L., Pincheira, R., Emerson, R., Bigby, R., Nakahara, H., et al. (2007). Enhanced peri-toeal ovarian tumor dissemination by tissue transglutaminase. *Cancer Res.* 67, 7194–7202.

Sharma, M., Pampanella, F., Nemes, C., Benharrouga, M., So, L., Du, K., et al. (2004). Mislocalizing diverts CFTR from recycling to degradation: quality control at early endosomes. *J. Cell Biol.* 164, 923–933.

Sinha, S., and Levine, B. (2008). The autophagy effector Beclin 1: a novel BH3-onlyprotein. *Oncoogene* 27(Suppl. 1), S137–S148.

Sloane, P. A., and Rowe, S. M. (2010). Cystic fibrosis transmembrane conductance regulator protein repair as a therapeutic strategy in cystic fibrosis. *Curr. Opin. Pulm. Med.* 16, 591–597.

Sridhar, S., Botbol, Y., MacLean, F., and Caero, A. M. (2012). Autophagy and disease: always two sides to a problem. *J. Pathol.* 226, 255–273.

Taylor, J. P., Tanaka, F., Robitschek, J., Sondová, C. M., Taye, A., Markovic-Plese, S., et al. (2003). Aggresomes protect cells by enhancing the degradation of toxic polyglutamine containing protein. *Hum. Mol. Genet.* 12, 749–757.

Tempe, D., Pieczycky, M., and Bossis, G. (2008). SUMO under stress. *Biochem. Soc. Trans.* 36, 874–878.

Van Goor, F., Hadida, S., Grootenhuis, P. D., Burton, B., Stack, J. H., Straley, K. S., et al. (2011). Correction of the F508del-CFTR protein processing defect in vitro by the investigational drug VX-809. *Proc. Natl. Acad. Sci. U.S.A.* 108, 18843–18848.

Van Goor, F., Straley, K. S., Cao, D., Gonza-delz, J., Hadida, S., Hazlewood, A., et al. (2006). Rescue of DeltaF508-CFTR trafficking and gating in human cystic fibrosis airway primary cultures by small molecules. *Am. J. Physiol. Lung Cell Mol. Physiol.* 290, L1117–L1130.

Verkman, A. S., and Gaillet, L. J. (2009). Chloride channels as drug targets. *Nat. Rev. Drug Discov.* 8, 153–171.

Verkman, A. S., Lukacs, G. L., and Gaillet, L. J. (2006). CFTR chloride channel drug discovery—inhibitors as anti diarrheals and activators for therapy of cystic fibrosis. *Curr. Pharm. Des.* 12, 2235–2247.

Vij, N., Maruz, S., and Zeitz, P. L. (2009). CFTR is a negative regulator of NF kappa B mediated innate immune response. *PLoS ONE* 4:e664. doi:10.1371/journal.pone.0004664.

Ward, C. L., Omura, S., and Kopito, R. R. (2005a). Cystic fibrosis airway epithelial Ca2+ i-signaling: the mechanism for the larger agonist-mediated hyperinflammatory response in human cystic fibrosis airway epithelia. *J. Biol. Chem.* 280, 17798–17806.

Received: 10 October 2012; accepted: 01 January 2013; published online: 21 January 2013.

Citation: Villella VR, Esposito S, Bruscia EM, Mauiri MC, Raza V, Kroeme G and Mauiri I (2013) Targeting the intracellular environment in cystic fibrosis: restoring autophagy as a novel strategy to circumvent the CFTR defect. *Front. Pharmacol.* 4:1. doi: 10.3389/fphar.2013.00001

This article was submitted to Frontiers in Pharmacology of Ion Channels and Channelopathies, a specialty of Frontiers in Pharmacology.

Copyright © 2013 Villella, Esposito, Bruscia, Mauiri, Raza, Kroemer and Mauiri. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in other forums, provided the original authors and source are credited and subject to any copyright notices concerning any third-party graphics etc.